Jim Petrik
Overview
Explore the profile of Jim Petrik including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
34
Citations
544
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
21.
Dynes J, Osz K, Hooper A, Petrik J
Biol Reprod
. 2017 Oct;
97(3):449-465.
PMID: 29024988
Chemotherapy can cause early menopause or infertility in women and have a profound negative impact on the quality of life of young female cancer survivors. Various factors are known to...
22.
Linnerth-Petrik N, Santry L, Moorehead R, Jucker M, Wootton S, Petrik J
Oncotarget
. 2016 Aug;
7(46):74820-74833.
PMID: 27533079
Ovarian cancer remains a significant therapeutic problem and novel, effective therapies are needed. Akt is a serine-threonine kinase that is overexpressed in numerous cancers, including ovarian. Mammalian cells express three...
23.
Greenaway J, Virtanen C, Osz K, Revay T, Hardy D, Shepherd T, et al.
Oncotarget
. 2016 Jun;
7(30):47343-47365.
PMID: 27329838
Epithelial ovarian cancer (EOC) is the most lethal gynecological cancer and often is not detected until late stages when cancer cells transcoelomically metastasize to the abdomen and typically become resistant...
24.
Russell S, Duquette M, Liu J, Drapkin R, Lawler J, Petrik J
FASEB J
. 2014 Nov;
29(2):576-88.
PMID: 25395453
Most women are diagnosed with epithelial ovarian cancer (EOC) at advanced stage, where therapies have limited effectiveness and the long-term survival rate is low. We evaluated the effects of combined...
25.
Osz K, Ross M, Petrik J
Reprod Biol Endocrinol
. 2014 Mar;
12:21.
PMID: 24628875
Background: Ovarian angiogenesis is a complex process that is regulated by a balance between pro- and anti-angiogenic factors. Physiological processes within the ovary, such as folliculogenesis, ovulation, and luteal formation...
26.
ABT-898 induces tumor regression and prolongs survival in a mouse model of epithelial ovarian cancer
Campbell N, Greenaway J, Henkin J, Petrik J
Mol Cancer Ther
. 2011 Aug;
10(10):1876-85.
PMID: 21844212
Epithelial ovarian cancer (EOC) is the most lethal gynecologic malignancy and is often not diagnosed until late stages due to its asymptomatic nature. Women diagnosed with EOC typically undergo surgical...
27.
Petre M, Petrik J, Ellis R, Inman M, Holloway A, Labiris N
Int J Toxicol
. 2011 Mar;
30(2):244-52.
PMID: 21378373
Many women are unable to quit smoking during pregnancy and therefore are prescribed drugs, including nicotine (nicotine replacement therapy [NRT]), to aid with smoking cessation. However, the consequences to the...
28.
Campbell N, Greenaway J, Henkin J, Moorehead R, Petrik J
Neoplasia
. 2010 Mar;
12(3):275-83.
PMID: 20234821
Epithelial ovarian cancer (EOC) comprises approximately 90% of ovarian cancers and arises from the surface epithelium. Typical treatment of EOC involves cytoreductive surgery combined with chemotherapy. More recent therapies have...
29.
Greenaway J, Henkin J, Lawler J, Moorehead R, Petrik J
Mol Cancer Ther
. 2009 Jan;
8(1):64-74.
PMID: 19139114
Epithelial ovarian cancer (EOC) is the fifth most common cancer in women and is characterized by a low 5-year survival rate. One strategy that can potentially improve the overall survival...
30.
Greenaway J, Moorehead R, Shaw P, Petrik J
Gynecol Oncol
. 2007 Nov;
108(2):385-94.
PMID: 18036641
Objective: Ovarian cancer is the fourth leading cause of cancer-related deaths among women and is among the least understood of all cancers. The objective of this study was to determine...